Literature DB >> 21637317

Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

Catarina Dias1, David A Isenberg.   

Abstract

Autoimmune rheumatic diseases (ARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome (SS), have consistently been associated with the development of B-cell non-Hodgkin lymphoma (BCNHL). In this Review, we focus on reports published since 2006 and summarize the data regarding the BCNHL subtypes and clinical findings associated with this increased risk. Patients with these ARD, particularly those with detectable autoantibodies and systemic involvement, are at increased risk of developing BCNHL, especially diffuse large B-cell lymphoma and marginal zone lymphoma. SS shows the strongest association with BCNHL. Male sex, advanced age, prolonged disease course and increased disease severity, but not family history of autoimmune conditions, seem to be associated with an increased risk of non-Hodgkin lymphoma. Chronic immune stimulation, genetic and environmental factors and some immunosuppressive drugs might be involved in lymphomagenesis in these patients. The reason why some ARD are associated with BCNHL and other autoimmune diseases are not remains unclear. These associations are important as they provide information about the mechanisms of lymphomagenesis, and might help identify new therapeutic targets.

Entities:  

Mesh:

Year:  2011        PMID: 21637317     DOI: 10.1038/nrrheum.2011.62

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  58 in total

1.  Cancer: an inflammatory link.

Authors:  Fran Balkwill; Lisa M Coussens
Journal:  Nature       Date:  2004-09-23       Impact factor: 49.962

2.  Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.

Authors:  Luca Quartuccio; Martina Fabris; Sara Salvin; Marta Maset; Ginevra De Marchi; Salvatore De Vita
Journal:  Int J Rheumatol       Date:  2010-01-28

3.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

4.  Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.

Authors:  Karin Hellgren; Karin E Smedby; Nils Feltelius; Eva Baecklund; Johan Askling
Journal:  Arthritis Rheum       Date:  2010-05

Review 5.  The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Expert Opin Pharmacother       Date:  2007-09       Impact factor: 3.889

6.  Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

Authors:  M Voulgarelis; S Giannouli; D Anagnostou; A G Tzioufas
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 8.  B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Nat Clin Pract Rheumatol       Date:  2007-10

Review 9.  Epstein-Barr virus and Burkitt lymphoma.

Authors:  G Brady; G J Macarthur; P J Farrell
Journal:  Postgrad Med J       Date:  2008-07       Impact factor: 2.401

10.  The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research.

Authors:  Alexandra Smith; Eve Roman; Debra Howell; Richard Jones; Russell Patmore; Andrew Jack
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

View more
  27 in total

1.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

2.  IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.

Authors:  Federica Riva; Maurilio Ponzoni; Domenico Supino; Maria Teresa Sabrina Bertilaccio; Nadia Polentarutti; Matteo Massara; Fabio Pasqualini; Roberta Carriero; Anna Innocenzi; Achille Anselmo; Tania Veliz-Rodriguez; Giorgia Simonetti; Hans-Joachim Anders; Federico Caligaris-Cappio; Alberto Mantovani; Marta Muzio; Cecilia Garlanda
Journal:  Cancer Immunol Res       Date:  2019-04-24       Impact factor: 11.151

3.  B-cell tolerance defects in the B6.Aec1/2 mouse model of Sjögren's syndrome.

Authors:  Wenzhao Meng; Yongmei Li; Emily Xue; Minoru Satoh; Ammon B Peck; Philip L Cohen; Robert A Eisenberg; Eline T Luning Prak
Journal:  J Clin Immunol       Date:  2012-02-17       Impact factor: 8.317

4.  Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.

Authors:  Shweta Jain; Jerrold M Ward; Dong-Mi Shin; Hongsheng Wang; Zohreh Naghashfar; Alexander L Kovalchuk; Herbert C Morse
Journal:  Am J Pathol       Date:  2017-07-17       Impact factor: 4.307

Review 5.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

6.  Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease.

Authors:  Tomoyuki Kondo; Takaaki Tsunematsu; Akiko Yamada; Rieko Arakaki; Masako Saito; Kunihiro Otsuka; Satoko Kujiraoka; Aya Ushio; Mie Kurosawa; Yasusei Kudo; Naozumi Ishimaru
Journal:  Lab Invest       Date:  2016-01-25       Impact factor: 5.662

7.  Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

Authors:  F Ciccia; G Guggino; A Rizzo; M Bombardieri; S Raimondo; F Carubbi; A Cannizzaro; G Sireci; F Dieli; G Campisi; R Giacomelli; Paola Cipriani; G De Leo; R Alessandro; G Triolo
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

8.  Epidemiologic overview of malignant lymphoma.

Authors:  Jooryung Huh
Journal:  Korean J Hematol       Date:  2012-06-26

Review 9.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

10.  Non-Hodgkin's lymphoma of the synovium discovered in total knee arthroplasty: a case report.

Authors:  Jetze Visser; Vincent J J F Busch; Ineke M de Kievit-van der Heijden; Arno M ten Ham
Journal:  BMC Res Notes       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.